Bionano Genomics (BNGO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Executive summary
Annual meeting scheduled for May 14, 2026, to be held virtually for stockholders of record as of March 19, 2026.
Proxy materials, including the proxy statement and annual report, are available online, with options to request paper or email copies.
Voting matters and shareholder proposals
Election of two Class II directors: Albert Luderer, Ph.D., and Kristiina Vuori, M.D., Ph.D.
Advisory vote to approve compensation of named executive officers.
Ratification of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board of directors and corporate governance
Board recommends voting in favor of all three proposals presented at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bionano Genomics
- Seeks to raise $400 million for operations and R&D amid ongoing losses and capital needs.BNGO
Registration filing8 May 2026 - Board recommends approval of director elections, executive pay, and auditor ratification, with ESG focus.BNGO
Proxy filing2 Apr 2026 - 2025 saw revenue of $28.5M, margin gains, and a 2026 outlook for $30–$33M growth.BNGO
Q4 202523 Mar 2026 - Board leadership transitioned, all proposals approved, and no stockholder questions were raised.BNGO
AGM 20243 Feb 2026 - Q2 revenue dropped 10% to $7.8M; OGM installs up 29%, but liquidity risks persist.BNGO
Q2 20242 Feb 2026 - Stratys adoption accelerates as new CPT code and workflow advances drive clinical and market growth.BNGO
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Shifting to a capital-efficient, recurring revenue model with streamlined operations and focused growth.BNGO
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Revenue down 35%, OGM and flowcell sales up, but urgent funding needed for ongoing operations.BNGO
Q3 202414 Jan 2026 - Share issuance and reverse stock split proposals both approved by stockholders.BNGO
EGM 202510 Jan 2026